title: Phase II study of uracil-tegafur plus cisplatin in patients with previously untreated advanced non-small cell lung cancer.
abstract: OBJECTIVE
  A multi-institutional phase II trial combining uracil-tegafur (UFT) and cisplatin (CDDP) was conducted in patients with previously untreated advanced non-small cell lung cancer (NSCLC) to evaluate the safety and efficacy of this combined treatment regimen.
  
  
  METHODS
  The entry criteria for this study were previously untreated NSCLC, measurable disease, age <80 years, performance status <2, and adequate haematological, hepatic and renal function. Patients were treated with 400 mg/m(2) oral UFT from day 1 to day 14 and 80 mg/m(2) cisplatin on day 15. The treatment course was repeated every 3 weeks.
  
  
  RESULTS
  Of the 68 patients enrolled, 64 (27 with stage IIIB and 37 with stage IV disease) were eligible for treatment. Twenty of the 64 patients responded to the chemotherapy (response rate 31.3%; 95% CI 21.2-43.4%). The median survival time was 8.6 months, and the 1-year survival was 41.5%. Haematological toxicity >or=WHO grade 3 was seen in 3 (4.7%) patients. For non-haematological toxicities, anorexia with WHO grade 3 was seen in 8 (12.5%) patients, nausea and vomiting with WHO grade 3 in 4 (6.3%), diarrhoea with WHO grade 4 in 1 (1.6%), and liver dysfunction with WHO grade 4 in 1 (1.6%) patient.
  
  
  CONCLUSIONS
  The combination of oral UFT plus cisplatin was found to be a safe and active treatment against advanced NSCLC. The observed low toxicity of this combined regimen may warrant its application to the treatment of elderly patients.
authors.affiliation: Research Institute for Diseases of the Chest, Kyushu University, Fukuoka, Japan. koichi-t@kokyu.med.kyushu-u.ac.jp
authors.forename: Koichi
authors.initials: K
authors.lastname: Takayama
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kawasaki
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ninomiya
authors.forename: Akira
authors.initials: A
authors.lastname: Motohiro
authors.forename: Masaki
authors.initials: M
authors.lastname: Fujita
authors.forename: Kentaro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Akira
authors.initials: A
authors.lastname: Kajiki
authors.forename: Fumiyuki
authors.initials: F
authors.lastname: Iwami
authors.forename: Naoki
authors.initials: N
authors.lastname: Miyazaki
authors.forename: Miiru
authors.initials: M
authors.lastname: Izumi
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hara
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakanishi
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D005641:Tegafur; D014498:Uracil; D002945:Cisplatin